We focused on antibody-dependent cellular cytotoxicity (ADCC), one of the efficacy in vivo of Herceptin (trastuzumab) which is a humanized monoclonal antibody against HER2, for patients with HER2-overexpressing breast cancer. As a result, it seems likely that antibody-dependent cellular cytotoxicity (ADCC) plays an important role in the Herceptin-dependent cytotoxicity. Also, it is revealed that taxanes enhances cytotoxicity of natural killer cells, as a immune lymphocytes, due to inducing both perforin and granzyme B expressions. Taken together, these findings suggest that the combination of chemotherapy and Herceptin with various types of activated lymphocytes may be a resonable therapeutic strategy for HER2-overexpressing recurrent breast cancer, inducing effectively ADCC.
|Number of pages||6|
|Publication status||Published - 2005|
All Science Journal Classification (ASJC) codes
- Cancer Research